Predicting Future Errors During Skill Performance
NCT06707207
Recruiting
Background: Many tasks people do every day require a series of individual movements. Control over these movements is called motor skills. But even highly skilled people can make mistakes. Researchers have found that they can predict when a person will make a mistake 0.1 second before it happens. Now, they want to find out if they can increase that time up to 1 second-long enough to warn the person and prevent the mistake. Objective: To see if motor skill errors can be detected up to 1 second... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
07/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy
Register for Updates
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
NCT06896162
Recruiting
This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for patients with stage IV solid tumor malignancies (breast, lung, colorectal, and bladder cancers). The purpose of this study is to investigate whether intervention from a centralized precision oncology navigator and expert review of NGS results by the precision oncology pharmacist will increase orderin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina
Conditions: Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Register for Updates
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT01174121
Recruiting
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. Researchers want to know if TIL shrink s tumors in people with digestive tract, urothelial, breast, or ovarian/endometrial cancer... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
07/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
Register for Updates
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
NCT03858205
Recruiting
This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: City of Hope, Duarte, California +8 locations
Conditions: Bone Pain, Metastatic Malignant Neoplasm in the Bone, Plasma Cell Myeloma
Register for Updates
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
NCT05237934
Recruiting
Background: Neuroendocrine neoplasm (NENs)are rare cancers arising from the neuroendocrine cells and can affect almost any part of the body. They vary from low grade neuroendocrine tumors (NETs) to high grade neuroendocrine carcinomas (NECs). These tumors often occur in the gastrointestinal tract, pancreas, lungs, adrenal medulla (pheochromocytomas) or adrenal cortex (adrenocortical cancer) and other areas of the body mentioned below: * Gastroenteropancreatic neuroendocrine tumors (GEP-NET): s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neuroendocrine Tumors, Carcinoma, Neuroendocrine
Register for Updates
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
NCT05554380
Recruiting
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +206 locations
Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
Gastroparesis Registry 4
NCT05846802
Recruiting
The Gastroparesis Registry 4 (GpR4) is an observational study of patients with symptoms of gastroparesis (Gp) and functional dyspepsia (FD) with either delayed or normal gastric emptying. To better understand these disorders, this registry will capture demographic, clinical, physiological, questionnaire, and patient outcome data to characterize the patients and their clinical course. Participants will complete several questionnaires, complete a nutrient drink test and have a gastric emptying stu... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/10/2025
Locations: Jay Pasricha, Scottsdale, Arizona +5 locations
Conditions: Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus Type I, Gastroparesis Due to Diabetes Mellitus Type II, Functional Disorder of Gastrointestinal Tract, Gastro-Intestinal Disorder
Register for Updates
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
NCT06181136
Recruiting
This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). The core study period is 25 weeks (approximately 6 months) and is followed by a 72-week (approximately 18 month) open-label extension (OLE). Participants with MPS IIIA will be enrolled in two planned cohorts, and additional participants with MPS IIIA may be enrolled in three... Read More
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
07/10/2025
Locations: UCSF Benioff Children's Hospital Oakland, Oakland, California +3 locations
Conditions: Mucopolysaccharidosis Type IIIA
Register for Updates
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
NCT06425549
Recruiting
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/10/2025
Locations: Ps0021 50162, Fountain Valley, California +46 locations
Conditions: Moderate to Severe Plaque Psoriasis
Register for Updates
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325
Recruiting
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/10/2025
Locations: Sl0044 50058, Avondale, Arizona +148 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia
NCT06744283
Recruiting
Background: Fanconi anemia (FA) is a rare, inherited cancer syndrome. FA causes a range of physical issues. Children with FA may have abnormal features; these may include a small head and eyes and issues with their internal organs. Young adults have a much higher risk of cancer. To screen for these cancers, people with FA may need to pursue many visits with different doctors. This constant need for cancer screening may cause anxiety for people with FA. Objective: To learn more about anxiety r... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/10/2025
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Fanconi Anemia
Register for Updates
Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopoietic Stem Cell Transplant
NCT06904053
Recruiting
Infections are a major cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplant (HSCT). The purpose of this study is to evaluate if metagenomic next-generation sequencing (mNGS) can detect microbial signatures in people undergoing HSCT, and if microbial identification can be correlated with clinical features of infection (e.g., fever). Participants undergoing HSCT as part of other studies at the NIH Clinical Center (CC) will provide blood before the transplant a... Read More
Gender:
ALL
Ages:
Between 3 years and 100 years
Trial Updated:
07/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hematopoietic Stem Cell Transplantation
Register for Updates